A nationwide post-marketing survey of knowledge,attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China

BackgroundHuman papillomavirus (HPV) vaccine has been increasingly discussed in mainland China since its first approval in 2016. To date, nearly all studies assessing HPV vaccine perceptions and attitudes were implemented during pre-licensure period. Therefore, the nationwide post-marketing survey was conducted to update knowledge, attitudes and practice on HPV vaccine among general population in mainland China.MethodsParticipants aged 18–45 years living in mainland China were recruited in April 2019 by multi-stage non-randomized sampling. Sociodemographic factors, HPV and HPV vaccine related awareness, knowledge, attitudes, vaccine uptake and potential obstacles were assessed in questionnaires. Bivariate analysis and multivariate regression were used to identify disparity among subgroups with different sociodemographic characteristics.Results4,000 women (32.1 ± 7.81y) and 1,000 men (31.8 ± 7.96y) were included in final analysis. Less than one third of participants had heard of HPV (female: 31%; male: 22%) and HPV vaccine (female: 34%; male: 23%). Knowledge score was also unfavorable on HPV (female: 3 out of 13; male: 1.8 out of 13) and HPV vaccine (female: 3 out of 6; male: 2 out of 5). Only 3% females had been vaccinated three years after HPV licensure in China, although willingness to get vaccinated among those unvaccinated were high (mean willingness score ± SD: female: 3.3 ± 0.97; male: 3.0 ± 0.98). Industry of employment and household income were the major factors related to awareness and knowledge of vaccine, whereas HPV and HPV vaccine awareness were key influential factors for willingness. The main obstacles of vaccination were safety concerns, lack of knowledge, and high price of HPV vaccines.ConclusionsFindings highlight a lack of vaccine awareness, knowledge, and poor uptake in mainland China and underscore the necessity of health education campaigns. The identified priority groups, contents to be delivered and practical obstacles could furthermore provide insight into health education to reduce disparities and accelerate HPV vaccine roll-out in China.     

Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries

Summary We studied the membrane effects of (1S,2S)-2-(2-[[3-2(benzimidazolyl) propyllmethylamino]ethyl)-6-fluoro-1,2,3,4-tetrahydro-l-isopropyl-2-naphthyl-methoxy-acetate dihydrochloride, Ro 40-5967, a new non-dihydropyridine (DHP) Ca²⁺ channel antagonist, on dog coronary and saphenous arterial vascular muscle cells using the whole-cell patch-clamp method. Long-lasting (L-type) inward currents in 20 mM Ba²⁺ were measured over a range of test potentials (300 ms) from –50 mV to + 90 mV from a holding potential of –80 mV in the presence of 1 M Bay k8644 (a DHP Ca²⁺ agonist). Ro 40-5967 caused a concentration-dependent suppression of Ca²⁺ channel currents in muscle cells from both arteries, with greater potency on coronary than saphenous arterial cells. The concentration of Ro 40-5967 which inhibited the magnitude of peak inward currents by 50% (IC₅₀) was estimated to be 1 M (n = 5) in muscle cells from coronary artery and 10 M (n = 4) in saphenous artery. Ro 40-5967 (1 M) decreased the amplitude of the activation current-voltage relationship for coronary L-type Ca²⁺ channel currents over a wider range of membrane potentials than verapamil, diltiazem, or nifedipine. In contrast, block of Ca²⁺ channel currents in saphenous artery cells by 1 M Ro 40-5967 was only observed at command potentials positive to 0 mV. Ro 40-5967 (1 M) significantly shifted the voltage-inactivation curve downward by 40% in coronary (n = 4), but only by 18% in saphenous arterial muscle cells (n = 3). The non-parallel shift of the coronary artery inactivation curve suggests that pronounced resting channel block is a notable feature of Ro 40-5967. The marked inhibition of Ba²⁺ current by 1 M Ro 40-5967 in the inactivation protocol in coronary arterial muscle cells was found over the entire range of membrane holding potentials tested, while inhibition in the saphenous artery inactivation curve occurred only from holding potentials more positive than –40 mV. Therefore, Ro 40-5967 is unique: 1) in acting over a wider range of voltages, on both instantaneous and resting Ca²⁺ currents, than other Ca²⁺ antagonists; 2) in producing more significant resting state block; and 3) in acting with selectivity for coronary over saphenous arteries.This research was supported by National Institutes of Health grants HL38537, HL38645, and by F. Hoffmann-La Roche, Basel, Switzerland     

移动平均数质控法在凝血试验中的应用

目的：建立凝血试验移动平均数质控法。方法：用移动平均数代替算术平均数,选择凝血验凝血酶原时间（ＰＴ）,活化的部分凝血激酶时间和纤维蛋白原３个项目,比较两种质控方法,同时用标准血浆作为质控。结果：当用适当的移动平滑系数时,移动平均数质控法既能排除病人标本非随机必的干扰,又能很好地反映试验前因素的影响。结论 ;移动平均数空法可用于凝血试验的实验室质控。     

透析中的终末期肾脏病可逆性探讨

透析中的终末期肾脏病 (ＥＳＲＤ) ,有不少医师认为已属不可治性 ,只能靠透析或肾移植维持生存。但也有人报道ＥＳＲＤ在透析治疗后有一定可逆缓解率〔1 ,2〕,部分患者肾功能可能恢复至氮质血症期甚至更低水平 ,并能脱离透析 ,避免肾移植或使之延后。本文回顾性分析本院 3 52例透析的ＥＳＲＤ病例 ,对ＥＳＲＤ的可逆缓解率及相关因素作初步探讨。对象与方法一、病例来源1992年 5月～ 1999年 9月曾在本院行血透治疗的所有慢性肾功能不全病例 ,符合下述条件者入选 :①患者有尿毒症的临床表现 (消化道症状及贫血为必备条件 ) ,肌酐清除率Ｃｃｒ…     

实验性局灶性脑缺血再灌注Fos蛋白的表达

目的　探讨大鼠局灶性脑缺血再灌注Fos蛋白表达的意义及其机制。方法　采用免疫组化法观察Fos蛋白在大鼠局灶性脑缺血再灌注后皮层和基底节区的动态变化。结果　Fos蛋白在大脑中动脉阻断 1h后 ,随再灌注时间延长其分布不同。基底节区持续时间长 ,阳性细胞多 ,而皮层持续时间短 ,阳性细胞少。其中再灌注 90min ,Fos蛋白表达最显著。大脑中动脉供血中心区皮层几无表达。结论　Fos蛋白的表达与神经细胞存活密切相关 ,出现Fos蛋白表达的区域神经元易于耐受缺血性损害而存活 ,可能是神经细胞自我保护机制之一 ,Fos蛋白的表达存在扩散抑制     

溶栓后早期T波的变化与冠脉再通的关系

目的 探讨急性心肌梗塞溶栓后早期Ｔ波的变化与闭塞冠脉再通的关系。方法 对８０例接受静脉溶栓治疗的ＡＭＩ患者进行前瞻性研究,根据溶栓后２４小时内有无Ｔ波倒置分为两组。依据临床间接判断冠脉再通的标准观察两组血管再通情况。结果 Ｔ波倒置组与未倒置组血管再通率分别为９３．１％和１１．３％（Ｐ〈０．０１）。结论 溶栓后早期Ｔ波倒置可作为判定梗塞相关血管再通的参考指标。     

PT和APTT标本留存时间与结果稳定性关系

目的探讨标本的待测时间对凝血酶原时间（PT）和活化部分促凝血酶原时间（APTT）试验结果的影响。方法：在室温下分别于采样后即刻、2、4、6、24h测定了40例志愿者的PT、AFTT,同时进行了血浆留存和全血留存结果的比较。结果：6h内无论全血留存标本还是血浆留存标本,其PT值和APPT值与初始值相比均无明显变化（P＞0．05）;24h全血留存标本PT值略升高（P＞0．05）,血浆留存标本较初始值延长14％,有显著差异（P＜0．05）。APTT值两类标本在6h内与初始值相比也无明显变化（P＞0．05）,24h均明显延长（P＜0．05）。结论：血浆留存标本或全血留存标本PT或APTT测定宜在采集标本后6h内完成。